Jazz Pharmaceuticals receives FDA approval for biliary tract cancer treatment-November 2024-www.financetom.com

Jazz Pharmaceuticals receives FDA approval for biliary tract cancer treatment

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Jazz Pharmaceuticals receives FDA approval for biliary tract cancer treatment

Nov 20, 2024 7:13 PM

Nov 20 (Reuters) - The U.S. Food and Drug Administration

approved Jazz Pharmaceuticals' ( JAZZ ) drug, zanidatamab, for

the treatment of a type of biliary tract cancer, the company

said on Wednesday.

Previous page： Next page： Shell earns $1 billion a year from US crude trading, court filing shows

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Apr 28, 2024

...

Shell earns $1 billion a year from US crude trading, court filing shows

Apr 28, 2024

By Arathy Somasekhar and Ron Bousso HOUSTON, April 29 (Reuters) - Financial details of Shell's vast oil and gas trading business are some of the company's closest-held secrets. Documents in a lawsuit filed by a former employee, however, revealed its U.S. crude trading regularly earns around $1 billion every year. Testimony by a former head of Shell's U.S. crude trading...

Baidu, Tesla agree on mapping deal for FSD in China, sources say

Apr 28, 2024

BEIJING (Reuters) - Baidu, China's major internet search company, reached an agreement with Tesla to grant the car company access to its mapping license for data collection on China's public roads, two people familiar with the matter said. The deal clears a final regulatory hurdle for Tesla's driver assistance system, which Tesla calls Full Self Driving (FSD) to be offered...

Blackstone-owned Crown Resorts to cut up to 1,000 jobs as challenges mount

Apr 28, 2024

April 29 (Reuters) - Blackstone-owned Crown Resorts will cut up to 1,000 roles in Melbourne, Perth and Sydney, a spokesperson said on Monday, as weak economic conditions continue to impact its business and it struggles to keep up with regulatory obligations. ...